Overview Executive Committee Supervisory Board Locations
Overview Satraplatin Kinase Inhibitors
Stock

Key Figures

Financial Reports SEC Filings Corporate Governance Analyst Coverage Shareholder´s Meeting Webcasts Information Request
Press Releases Contact Information
Working for GPC Biotech Germany USA

More Info

Print preview

Print

Investor Relations


Key Figures

Key Figures

US GAAP

2007

2006

2005

Financial performance

Revenues, € in thousands

18,315

22,674

9,341

Research and Development expenses, € in thousands

51,437

64,707

55,684

Research and Development
of total operating expenses %

57

73

72

General and Administrative expenses, € in thousands

39,199

23,834

20,590

Net loss, € in thousands

(69,245)

(64,013)

(62,207)

Cash flow

Net cash used in operating activities, € in thousands

(66,719)

(36,622)

(42,787)

Cash used in purchase of property, equipment and licenses, € in thousands

(1,581)

(1,878)

(4,549)

Net cash burn(1), € in thousands

(68,300)

(38,500)

(47,336)

Net cash provided by financing activities, € in thousands

40,415

41,593

11,501

Balance sheet data

Cash, cash equivalents, restricted cash, marketable securities and short-term investments, € in thousands

65,214

97,053

95,235

Total assets, € in thousands

73,386

107,519

139,263

Shareholders’ equity, € in thousands

38,603

67,175

83,533

Equity ratio(2) %

53

62

60

Share data

Earnings per share (basic and diluted)(3), €

(1.91)

(1.95)

(2.08)

Dividends, in €

-

-

-

Number of shares issued and outstanding as of Dec. 31, in thousands

36,837

33,895

30,152

Weighted average number of shares outstanding, in thousands

36,182

32,840

29,877

Additional information

Employees as of Dec. 31

158

245

222

1 Cash flow from operating activities plus cash used in purchase of property, equipment and licenses.

2 Total equity/total assets

3 Based on the weighted average number of shares outstanding.

Investor Relations | Key Figures